Funding high-cost pharmaceuticals

This position paper, Funding High Cost Biotechnology under the Pharmaceutical Benefits Scheme, was prepared to aid discussions by stakeholders in the scheme at a forum in Sydney on 7 March 2002. The aim was to identify and assess possible mechanisms or models for funding new high cost biotechnology products and other innovative targeted therapies that are not achieving listing on the current Pharmaceutical Benefits Scheme.